PMID- 37871702 OWN - NLM STAT- MEDLINE DCOM- 20240115 LR - 20240115 IS - 1569-8041 (Electronic) IS - 0923-7534 (Linking) VI - 35 IP - 1 DP - 2024 Jan TI - Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial. PG - 107-117 LID - S0923-7534(23)04021-8 [pii] LID - 10.1016/j.annonc.2023.10.003 [doi] AB - BACKGROUND: Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in patients with susceptible FGFR3/2 alterations (FGFRalt) who progressed after platinum-containing chemotherapy. FGFR-altered tumours are enriched in luminal 1 subtype and may have limited clinical benefit from anti-programmed death-(ligand) 1 [PD-(L)1] treatment. This cohort in the randomized, open-label phase III THOR study assessed erdafitinib versus pembrolizumab in anti-PD-(L)1-naive patients with mUC. PATIENTS AND METHODS: Patients >/=18 years with unresectable advanced/mUC, with select FGFRalt, disease progression on one prior treatment, and who were anti-PD-(L)1-naive were randomized 1 : 1 to receive erdafitinib 8 mg once daily with pharmacodynamically guided uptitration to 9 mg or pembrolizumab 200 mg every 3 weeks. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. RESULTS: The intent-to-treat population (median follow-up 33 months) comprised 175 and 176 patients in the erdafitinib and pembrolizumab arms, respectively. There was no statistically significant difference in OS between erdafitinib and pembrolizumab [median 10.9 versus 11.1 months, respectively; hazard ratio (HR) 1.18; 95% confidence interval (CI) 0.92-1.51; P = 0.18]. Median PFS for erdafitinib and pembrolizumab was 4.4 and 2.7 months, respectively (HR 0.88; 95% CI 0.70-1.10). ORR was 40.0% and 21.6% (relative risk 1.85; 95% CI 1.32-2.59) and median duration of response was 4.3 and 14.4 months for erdafitinib and pembrolizumab, respectively. 64.7% and 50.9% of patients in the erdafitinib and pembrolizumab arms had >/=1 grade 3-4 adverse events (AEs); 5 (2.9%) and 12 (6.9%) patients, respectively, had AEs that led to death. CONCLUSIONS: Erdafitinib and pembrolizumab had similar median OS in this anti-PD-(L)1-naive, FGFR-altered mUC population. Outcomes with pembrolizumab were better than assumed and aligned with previous reports in non- FGFR-altered populations. Safety results were consistent with the known profiles for erdafitinib and pembrolizumab in this patient population. CI - Copyright (c) 2023 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. FAU - Siefker-Radtke, A O AU - Siefker-Radtke AO AD - Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: asiefker@mdanderson.org. FAU - Matsubara, N AU - Matsubara N AD - Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan. FAU - Park, S H AU - Park SH AD - Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. FAU - Huddart, R A AU - Huddart RA AD - Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK. FAU - Burgess, E F AU - Burgess EF AD - Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, USA. FAU - Ozguroglu, M AU - Ozguroglu M AD - Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. FAU - Valderrama, B P AU - Valderrama BP AD - Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain. FAU - Laguerre, B AU - Laguerre B AD - Department of Medical Oncology, Centre Eugene Marquis, Rennes, France. FAU - Basso, U AU - Basso U AD - Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy. FAU - Triantos, S AU - Triantos S AD - Janssen Research & Development, Spring House, USA. FAU - Akapame, S AU - Akapame S AD - Janssen Research & Development, Spring House, USA. FAU - Kean, Y AU - Kean Y AD - Janssen Research & Development, Spring House, USA. FAU - Deprince, K AU - Deprince K AD - Janssen Research & Development, Beerse, Belgium. FAU - Mukhopadhyay, S AU - Mukhopadhyay S AD - Janssen Research & Development, Raritan, USA. FAU - Loriot, Y AU - Loriot Y AD - Department of Cancer Medicine, INSERM U981, Gustave Roussy, Universite Paris-Saclay, Villejuif, France. CN - THOR cohort 2 investigators LA - eng PT - Clinical Trial, Phase III PT - Journal Article PT - Randomized Controlled Trial DEP - 20231021 PL - England TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology JID - 9007735 RN - DPT0O3T46P (pembrolizumab) RN - 890E37NHMV (erdafitinib) RN - 0 (Antibodies, Monoclonal, Humanized) RN - 0 (Pyrazoles) RN - 0 (Quinoxalines) SB - IM MH - Humans MH - *Carcinoma, Transitional Cell/drug therapy/pathology MH - *Urinary Bladder Neoplasms/drug therapy/pathology MH - Antibodies, Monoclonal, Humanized MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Pyrazoles MH - *Quinoxalines OTO - NOTNLM OT - FGFR OT - erdafitinib OT - metastatic urothelial cancer OT - overall survival OT - pembrolizumab OT - safety COIS- Disclosure AOS has received honoraria from Astellas, AstraZeneca, Bavarina Nordic, Basilea, Bicycle Therapeutics, Bristol Myers Squibb, G1 Therapeutics, Genentech, Gilead, Ideeya Biosciences, Immunomedics, Janssen, Loxo, Merck, Mirati, Nektar, Seattle Genetics, and Taiho and research funding (institutional) from Basilea Pharmaceutica, Bristol Myers Squibb, Janssen, Loxo, Merck, Millennium, and Nektar. NM has received honoraria (personal) from Sanofi; research funding (institutional) from Amgen, Astellas Pharma, AstraZeneca, Bayer, Chugai Pharm, Eisai, Janssen, Lilly, Merck Sharp & Dohme, Pfizer, PRA Health Science, Roche, Seagen, Taiho, and Takeda; and has been reimbursed for travel, accommodations, or expenses (personal) from Pfizer. SHP has received honoraria from Merck, Ono Pharma Korea, and Pfizer; served as a consultant for Janssen Oncology; and received institutional research support from Merck Sharp & Dohme. RAH has received personal fees from Aspen Parkside Hospital, Merck, and Pfizer; consulting fees from Bristol Myers Squibb, Roche, Merck Sharp & Dohme, Janssen Oncology, Nektar, and Bayer; honoraria from Janssen Oncology; has been reimbursed for travel, accommodations, or expenses from Janssen Oncology, Roche/Genentech, MSD Oncology, and Nektar; has other financial or non-financial interests with Merck Sharp & Dohme, Roche, Bristol Myers Squibb, and Janssen; and has a leadership or fiduciary role at Cancer Clinic London Liability Partnership, outside of the submitted work. EFB has received honoraria from Exelixis, Janssen, Merck, Novartis, and Pfizer; research funding (personal) from Astellas and Pfizer; and research funding (institutional) from Astellas, Bristol Myers Squibb, Janssen, Merck, Pfizer, Roche/Genentech, and Seagen. NH has received consulting fees from Astellas, AstraZeneca, Bristol Myers Squibb, Gilead, Janssen, Merck, and Pfizer. MO has served as a consultant for Sanofi, Astellas, and Bayer; has participated in a speaker's bureau for Regeneron; and has been reimbursed for travel, accommodation, and expenses by Sanofi and Regeneron. BPV has served as a consultant for Astellas Pharma, Astra Zeneca, Bayer, Bristol Myers Squibb, and Novartis; has received honoraria from Astellas, Bristol Myers Squibb, Eusa Pharma, Ipsen, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Roche; and has been reimbursed for travel, accommodations, or expenses by Bristol Myers Squibb, Janssen-Cilag, Merck, Novartis, and Pfizer. BL has received honoraria from Janssen and has been reimbursed for travel, accommodations, or expenses by Astellas, Jassen, and Pfizer. UB has participated in a speaker's bureau for and/or received travel and accommodation grants from Astellas, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, and Merck Sharp & Dohme and has received research funding (institutional) from Ipsen. YK serves as a functional service provider for Janssen. ST, SA, KD, and SM are employed by Janssen Research & Development and have stock or stock options with Johnson & Johnson. YL has received consulting fees from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Immunomedics, Janssen (and institutional), MSD Oncology (and institutional), Loxo/Lilly, Pfizer/EMD Serono, Roche, and Taiho Pharmaceutical; has been reimbursed for travel, accommodations, or expenses from Astellas, AstraZeneca, Janssen Oncology, MSD Oncology, and Roche; and has received research funding (institutional) from Astellas Pharma, AstraZeneca, Basilea, Bristol Myers Squibb, Exelixis, Gilead Sciences, Incyte, Janssen Oncology, Merck KGaA, MSD Oncology, Nektar, Pfizer, Roche, Sanofi, and Taiho Pharmaceutical. FIR - Bastick, Patricia IR - Bastick P FIR - Sewak, Sanjeev IR - Sewak S FIR - Tran, Ben IR - Tran B FIR - Pichler, Martin IR - Pichler M FIR - Shariat, Shahrokh IR - Shariat S FIR - Rottey, Sylvie IR - Rottey S FIR - Schatteman, Peter IR - Schatteman P FIR - Schrijvers, Dirk IR - Schrijvers D FIR - Verschaeve, Vincent IR - Verschaeve V FIR - Vulsteke, Christof IR - Vulsteke C FIR - Barros Leite Ferreira, Luiza Aleixo IR - Barros Leite Ferreira LA FIR - de Santana Gomes Andrea Juliana, Pereira IR - de Santana Gomes Andrea Juliana P FIR - Junior, Joao Antonio IR - Junior JA FIR - Azevedo, Sergio IR - Azevedo S FIR - Bastos, Diogo IR - Bastos D FIR - Borges, Giuliano IR - Borges G FIR - Dettino, Aldo IR - Dettino A FIR - Antonio, Pires Luis IR - Antonio PL FIR - Luz, Murilo IR - Luz M FIR - Martins, Suelen IR - Martins S FIR - Mota, Jose Mauricio IR - Mota JM FIR - Toledo, Joseane IR - Toledo J FIR - Eigl, Bernhard IR - Eigl B FIR - Finch, Daygen IR - Finch D FIR - Gingerich, Joel IR - Gingerich J FIR - Dong, Haiying IR - Dong H FIR - Huang, Jian IR - Huang J FIR - Jin, Jie IR - Jin J FIR - Pan, Hongming IR - Pan H FIR - Sun, Zhongquan IR - Sun Z FIR - Tian, Ye IR - Tian Y FIR - Wan, Ben IR - Wan B FIR - Wu, Bin IR - Wu B FIR - Xu, Ting IR - Xu T FIR - Xue, Wei IR - Xue W FIR - Zhou, Fangjian IR - Zhou F FIR - Barthelemy, Philippe IR - Barthelemy P FIR - Borchiellini, Delphine IR - Borchiellini D FIR - Calcagno, Fabien IR - Calcagno F FIR - Carnot, Aurelien IR - Carnot A FIR - Cornillon, Pierre IR - Cornillon P FIR - Delva, Remy IR - Delva R FIR - Emambux, Sheik IR - Emambux S FIR - Houede, Nadine IR - Houede N FIR - Laguerre, Brigitte IR - Laguerre B FIR - Lauridant, Geraldine IR - Lauridant G FIR - Loriot, Yohann IR - Loriot Y FIR - Mahammedi, Hakim IR - Mahammedi H FIR - Maillet, Denis IR - Maillet D FIR - Pouessel, Damien IR - Pouessel D FIR - Roubaud, Guilhem IR - Roubaud G FIR - Schlurmann-Constans, Friederike IR - Schlurmann-Constans F FIR - Tosi, Diego IR - Tosi D FIR - Zanetta, Sylvie IR - Zanetta S FIR - Banek, Severine IR - Banek S FIR - Feyerabend, Susan IR - Feyerabend S FIR - Kramer, Mario IR - Kramer M FIR - Niegisch, Guenther IR - Niegisch G FIR - Nuhn, Philipp IR - Nuhn P FIR - Schnabel, Marco IR - Schnabel M FIR - Wuelfing, Christian IR - Wuelfing C FIR - Baka, Sofia IR - Baka S FIR - Bamias, Aristotelis IR - Bamias A FIR - Fountzilas, George IR - Fountzilas G FIR - Kalofonos, Harabolos IR - Kalofonos H FIR - Karalis, Konstantinos IR - Karalis K FIR - Kotsakis, Athanasios IR - Kotsakis A FIR - Timotheadou, Eleni IR - Timotheadou E FIR - Landherr, Laszlo IR - Landherr L FIR - Mangel, Laszlo IR - Mangel L FIR - Pe'er, Avivit IR - Pe'er A FIR - Levratovsky, Meital IR - Levratovsky M FIR - Basso, Umberto IR - Basso U FIR - Battelli, Nicola IR - Battelli N FIR - Cavo, Alessia IR - Cavo A FIR - De Giorgi, Ugo IR - De Giorgi U FIR - Doni, Laura IR - Doni L FIR - Galli, Luca IR - Galli L FIR - Gigante, Maria Olga IR - Gigante MO FIR - Guadalupi, Valentina IR - Guadalupi V FIR - Maio, Michele IR - Maio M FIR - Milesi, Laura IR - Milesi L FIR - Nole, Franco IR - Nole F FIR - Scagliotti, Giorgio IR - Scagliotti G FIR - Tortora, Giampaolo IR - Tortora G FIR - Fukasawa, Satoshi IR - Fukasawa S FIR - Harabayashi, Toru IR - Harabayashi T FIR - Kamiya, Naoto IR - Kamiya N FIR - Kawahara, Takashi IR - Kawahara T FIR - Kawakita, Mutsushi IR - Kawakita M FIR - Matsubara, Nobunaki IR - Matsubara N FIR - Matsumoto, Kazumasa IR - Matsumoto K FIR - Nishimura, Kazuo IR - Nishimura K FIR - Rikiya, Taoka IR - Rikiya T FIR - Shimizu, Nobuaki IR - Shimizu N FIR - Tagaki, Toshio IR - Tagaki T FIR - Kang, Taek Won IR - Kang TW FIR - Kim, Jwa Hoon IR - Kim JH FIR - Kim, SeHyun IR - Kim S FIR - Lee, Hyo Jin IR - Lee HJ FIR - Lee, Yun-Gyoo IR - Lee YG FIR - Rha, Sun Young IR - Rha SY FIR - Seo, Ho Kyung IR - Seo HK FIR - Los, Maartje IR - Los M FIR - Zurawski, Bogdan IR - Zurawski B FIR - Cortes, Paulo IR - Cortes P FIR - Faustino, Catia IR - Faustino C FIR - Vau, Nuno Sineiro IR - Vau NS FIR - da Luz, Ricardo IR - da Luz R FIR - Atduev, Vagif IR - Atduev V FIR - Kirtbaya, Dmitry IR - Kirtbaya D FIR - Kopyltsov, Evgeny IR - Kopyltsov E FIR - Lykov, Aleksandr IR - Lykov A FIR - Marat, Urmantsev IR - Marat U FIR - Orlov, Sergey IR - Orlov S FIR - Penkov, Konstantin IR - Penkov K FIR - Pirmagomedov, Albert IR - Pirmagomedov A FIR - Semenov, Andrey IR - Semenov A FIR - Varlamov, Sergey IR - Varlamov S FIR - Anguera, Georgia IR - Anguera G FIR - Domenech, Montserrat IR - Domenech M FIR - Girones, Regina IR - Girones R FIR - Gonzalez Del Alba, Aranzazu IR - Gonzalez Del Alba A FIR - Milagro, Nuria Lainez IR - Milagro NL FIR - Luque, Raquel IR - Luque R FIR - Ortega, Esther Martinez IR - Ortega EM FIR - Mellado, Begona IR - Mellado B FIR - Mendez Vidal, Maria Jose IR - Mendez Vidal MJ FIR - Fernandez, Esteban Nogales IR - Fernandez EN FIR - Valderrama, Begona Perez IR - Valderrama BP FIR - Marin, Alvaro Pinto IR - Marin AP FIR - Santander, Carmen IR - Santander C FIR - Huang, Yi-Hsiu IR - Huang YH FIR - Su, Wen-Pin IR - Su WP FIR - Wu, Hung-Chan IR - Wu HC FIR - Wu, WenJeng IR - Wu W FIR - Yu, Kai-Jie IR - Yu KJ FIR - Bilici, Ahmet IR - Bilici A FIR - Goker, Erdem IR - Goker E FIR - Gumus, Mahmut IR - Gumus M FIR - Karaoglu, Aziz IR - Karaoglu A FIR - Kefeli, Umut IR - Kefeli U FIR - Kose, Fatih IR - Kose F FIR - Ozguroglu, Mustafa IR - Ozguroglu M FIR - Tural, Deniz IR - Tural D FIR - Turk, Haci IR - Turk H FIR - Yalcin, Suayib IR - Yalcin S FIR - Bondarenko, Igor IR - Bondarenko I FIR - Khareba, Gennadii IR - Khareba G FIR - Kidik, Yana IR - Kidik Y FIR - Lychkovskyy, Oleksandr IR - Lychkovskyy O FIR - Sakalo, Valerii IR - Sakalo V FIR - Shevnia, Serghii IR - Shevnia S FIR - Stakhovskyy, Eduard IR - Stakhovskyy E FIR - Bahl, Amit IR - Bahl A FIR - Crabb, Simon IR - Crabb S FIR - Powles, Thomas IR - Powles T FIR - Sankey, Peter IR - Sankey P FIR - Sarwar, Mohammad IR - Sarwar M FIR - Benedetto, Pasquale IR - Benedetto P FIR - Burgess, Earle IR - Burgess E FIR - Dawson, Nancy IR - Dawson N FIR - Doshi, Gurjyot IR - Doshi G FIR - Fleming, Mark IR - Fleming M FIR - Maly, Joseph IR - Maly J FIR - Parikh, Mamta IR - Parikh M FIR - Waterhouse, David IR - Waterhouse D EDAT- 2023/10/24 00:41 MHDA- 2024/01/15 12:42 CRDT- 2023/10/23 19:27 PHST- 2023/09/19 00:00 [received] PHST- 2023/10/03 00:00 [revised] PHST- 2023/10/05 00:00 [accepted] PHST- 2024/01/15 12:42 [medline] PHST- 2023/10/24 00:41 [pubmed] PHST- 2023/10/23 19:27 [entrez] AID - S0923-7534(23)04021-8 [pii] AID - 10.1016/j.annonc.2023.10.003 [doi] PST - ppublish SO - Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21.